Javier Martínez-Picado

The combination of the antiretrovirals bictegravir and lenacapavir in a single tablet allows HIV treatment —previously based on multiple daily medications— to be simplified, according to the results of a new phase 3 clinical trial published in The Lancet. The trial, which included over 550 people living with HIV from 15 countries with a median age of 60, showed that the new treatment was just as effective at maintaining viral suppression as multi-drug regimens. Most participants were taking between two and eleven tablets daily, and around 40 % were on antiretrovirals more than once a day. The results were presented at the 2026 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, USA.

Stem cell transplants in cancer patients have achieved complete remission of HIV in a few cases in people who are also HIV-positive. However, in most cases, the donors were homozygous—with two identical copies of the gene—for a mutation in the CCR5 gene that is considered protective against the virus. A German team has now reported a new case of remission in a 60-year-old man with leukemia—called the “second Berlin patient”—in which the donor was heterozygous (only one of the two copies contained the mutation), which could broaden the alternatives. The results are published in the journal Nature.